γ-Secretase Modulator (GSM) Photoaffinity Probes Reveal Distinct Allosteric Binding Sites on Presenilin*

Background: Potent GSMs have been identified that lower Aβ42; however, the mechanism of modulation is not well understood. Results: The photoaffinity probe E2012-BPyne specifically labels PS1-NTF at a unique site. Conclusion: Acid and imidazole GSMs bind to distinct sites on PS1-NTF and are differentially affected by L458. Significance: Our results provide evidence for multiple binding sites within γ-secretase that confer specific modulatory effects. γ-Secretase is an intramembrane aspartyl protease that cleaves the amyloid precursor protein to produce neurotoxic β-amyloid peptides (i.e. Aβ42) that have been implicated in the pathogenesis of Alzheimer disease. Small molecule γ-secretase modulators (GSMs) have emerged as potential disease-modifying treatments for Alzheimer disease because they reduce the formation of Aβ42 while not blocking the processing of γ-secretase substrates. We developed clickable GSM photoaffinity probes with the goal of identifying the target of various classes of GSMs and to better understand their mechanism of action. Here, we demonstrate that the photoaffinity probe E2012-BPyne specifically labels the N-terminal fragment of presenilin-1 (PS1-NTF) in cell membranes as well as in live cells and primary neuronal cultures. The labeling is competed in the presence of the parent imidazole GSM E2012, but not with acid GSM-1, allosteric GSI BMS-708163, or substrate docking site peptide inhibitor pep11, providing evidence that these compounds have distinct binding sites. Surprisingly, we found that the cross-linking of E2012-BPyne to PS1-NTF is significantly enhanced in the presence of the active site-directed GSI L-685,458 (L458). In contrast, L458 does not affect the labeling of the acid GSM photoprobe GSM-5. We also observed that E2012-BPyne specifically labels PS1-NTF (active γ-secretase) but not full-length PS1 (inactive γ-secretase) in ANP.24 cells. Taken together, our results support the hypothesis that multiple binding sites within the γ-secretase complex exist, each of which may contribute to different modes of modulatory action. Furthermore, the enhancement of PS1-NTF labeling by E2012-BPyne in the presence of L458 suggests a degree of cooperativity between the active site of γ-secretase and the modulatory binding site of certain GSMs.

[1]  Feng Wang,et al.  BMS-708,163 targets presenilin and lacks notch-sparing activity. , 2012, Biochemistry.

[2]  K. Bales,et al.  Pharmacological Assessment of γ-Secretase Activity from Rodent and Human Brain , 2012 .

[3]  K. Bales,et al.  Development of clickable active site-directed photoaffinity probes for γ-secretase. , 2012, Bioorganic & medicinal chemistry letters.

[4]  B. de Strooper,et al.  The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.

[5]  D. Scheinberg,et al.  Familial Alzheimer Disease Presenilin-1 Mutations Alter the Active Site Conformation of γ-secretase* , 2012, The Journal of Biological Chemistry.

[6]  A. Sabirsh,et al.  First and Second Generation γ-Secretase Modulators (GSMs) Modulate Amyloid-β (Aβ) Peptide Production through Different Mechanisms , 2012, The Journal of Biological Chemistry.

[7]  Y. Shitaka,et al.  Differential Effects between γ-Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice , 2012, The Journal of Neuroscience.

[8]  S. Weggen,et al.  Presenilin Is the Molecular Target of Acidic γ-Secretase Modulators in Living Cells , 2012, PloS one.

[9]  T. Iwatsubo,et al.  Phenylpiperidine‐type γ‐secretase modulators target the transmembrane domain 1 of presenilin 1 , 2011, The EMBO journal.

[10]  J. B. Jordan,et al.  NSAID-based γ-secretase modulators do not bind to the amyloid-β polypeptide. , 2011, Biochemistry.

[11]  K. Bales,et al.  Piperidine acetic acid based γ-secretase modulators directly bind to Presenilin-1. , 2011, ACS chemical neuroscience.

[12]  Shao Q Yao,et al.  Proteome profiling reveals potential cellular targets of staurosporine using a clickable cell-permeable probe. , 2011, Chemical communications.

[13]  C. Haass,et al.  Novel γ-Secretase Enzyme Modulators Directly Target Presenilin Protein* , 2011, The Journal of Biological Chemistry.

[14]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[15]  S. Weggen,et al.  Substrate Sequence Influences γ-Secretase Modulator Activity, Role of the Transmembrane Domain of the Amyloid Precursor Protein* , 2011, The Journal of Biological Chemistry.

[16]  S. Sieber,et al.  Unraveling the protein targets of vancomycin in living S. aureus and E. faecalis cells. , 2011, Journal of the American Chemical Society.

[17]  N. Ramsden,et al.  Chronic treatment with a novel γ‐secretase modulator, JNJ‐40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease , 2011, British journal of pharmacology.

[18]  J. Richardson,et al.  Dynamics of Aβ42 Reduction in Plasma, CSF and Brain of Rats Treated with the γ-Secretase Modulator, GSM-10h , 2011, Neurodegenerative Diseases.

[19]  Daniel Oehlrich,et al.  γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. , 2011, Journal of medicinal chemistry.

[20]  Gregory W. Kauffman,et al.  Novel γ-secretase modulators: a review of patents from 2008 to 2010 , 2011, Expert opinion on therapeutic patents.

[21]  G. Multhaup,et al.  The amyloid precursor protein C-terminal fragment C100 occurs in monomeric and dimeric stable conformations and binds γ-secretase modulators. , 2011, Biochemistry.

[22]  B. Hyman,et al.  Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric site , 2010, Nature communications.

[23]  Xulun Zhang,et al.  Activation and intrinsic γ-secretase activity of presenilin 1 , 2010, Proceedings of the National Academy of Sciences.

[24]  Xulun Zhang,et al.  Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease , 2010, Neuron.

[25]  Petra Schneider,et al.  Exploring the chemical space of gamma-secretase modulators. , 2010, Trends in pharmacological sciences.

[26]  J. Macor,et al.  Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. , 2010, ACS medicinal chemistry letters.

[27]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[28]  R. Martone,et al.  Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. , 2009, Journal of medicinal chemistry.

[29]  M. Best,et al.  Click chemistry and bioorthogonal reactions: unprecedented selectivity in the labeling of biological molecules. , 2009, Biochemistry.

[30]  Raphael Kopan,et al.  The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism , 2009, Cell.

[31]  Kristin E. D. Coan,et al.  Promiscuous Aggregate-Based Inhibitors Promote Enzyme Unfolding , 2009, Journal of medicinal chemistry.

[32]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[33]  M. Wolfe,et al.  Substrate-targeting γ-secretase modulators , 2008, Nature.

[34]  B. Cravatt,et al.  Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. , 2008, Journal of the American Chemical Society.

[35]  Richard M. Page,et al.  Generation of Aβ38 and Aβ42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and γ-Secretase Modulation* , 2008, Journal of Biological Chemistry.

[36]  J. Taunton,et al.  Photo-leucine incorporation reveals the target of a cyclodepsipeptide inhibitor of cotranslational translocation. , 2007, Journal of the American Chemical Society.

[37]  P. Mehta,et al.  Humoral immune responses to peptides derived from the β-amyloid peptide C-terminal sequence , 2007, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[38]  M. Wolfe,et al.  The initial substrate-binding site of γ-secretase is located on presenilin near the active site , 2005 .

[39]  Anna E Speers,et al.  Profiling enzyme activities in vivo using click chemistry methods. , 2004, Chemistry & biology.

[40]  Chunjiang Yu,et al.  Regulated hyperaccumulation of presenilin-1 and the "gamma-secretase" complex. Evidence for differential intramembranous processing of transmembrane subatrates. , 2003, The Journal of biological chemistry.

[41]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[42]  S. Weggen,et al.  Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain* , 2003, Journal of Biological Chemistry.

[43]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[44]  T. Iwatsubo,et al.  Sulindac Sulfide Is a Noncompetitive γ-Secretase Inhibitor That Preferentially Reduces Aβ42 Generation* , 2003, The Journal of Biological Chemistry.

[45]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[46]  Graeme Irvine Stevenson,et al.  L-685,458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid β-Protein Precursor γ-Secretase Activity , 2000 .

[47]  Min Xu,et al.  Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1 , 2000, Nature.

[48]  Min Xu,et al.  Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Min Xu,et al.  Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state , 2000, Neurobiology of Aging.

[50]  B. de Strooper,et al.  Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. , 2012, Cold Spring Harbor perspectives in medicine.

[51]  D. Kovacs,et al.  The many substrates of presenilin/γ-secretase. , 2011, Journal of Alzheimer's disease : JAD.

[52]  K. Blennow,et al.  Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. , 2010, Journal of Alzheimer's disease : JAD.

[53]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .